Fapon Biotech, an IVD reagent raw materials and one-stop solutions provider, completed the acquisition of the remaining 60% stake in Sequlite, an enterprise that focuses on next-generation sequencing. Financial terms were not disclosed. "As Fapon Biotech is growing by leaps and bounds, I totally believe it has powerful strength in digging into cutting-edge diagnostic technology and providing one-stop solutions. Fapon Biotech has been a fantastic partner to Sequlite and we all look forward to a bright future where more people and organizations around the world may benefit from the power of NGS applied to healthcare," Millard Chan, Sequlite Co-founder and CEO.